Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Programmed Death ligand-1 (PD-L1) protein mediates immune suppression in cancer. Here, the authors show that in breast cancer, PD-L1 expression can be up regulated post-translationally by glycosylation, which in turn acts through inhibiting GSK3β-mediated PD-L1 degradation.
Guardado en:
Autores principales: | Chia-Wei Li, Seung-Oe Lim, Weiya Xia, Heng-Huan Lee, Li-Chuan Chan, Chu-Wei Kuo, Kay-Hooi Khoo, Shih-Shin Chang, Jong-Ho Cha, Taewan Kim, Jennifer L. Hsu, Yun Wu, Jung-Mao Hsu, Hirohito Yamaguchi, Qingqing Ding, Yan Wang, Jun Yao, Cheng-Chung Lee, Hsing-Ju Wu, Aysegul A. Sahin, James P. Allison, Dihua Yu, Gabriel N. Hortobagyi, Mien-Chie Hung |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/95bbbbb825d74f9a9d75ce9718db0cfa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
por: Jung-Mao Hsu, et al.
Publicado: (2018) -
Systems glycomics of adult zebrafish identifies organ-specific sialylation and glycosylation patterns
por: Nao Yamakawa, et al.
Publicado: (2018) -
Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation
por: Heng-Huan Lee, et al.
Publicado: (2021) -
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
por: Riyao Yang, et al.
Publicado: (2021) -
Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Lei Nie, et al.
Publicado: (2020)